Resources

Alliance of CGT Manufacturing Partners (ACGMP) founding members aim to help cell and gene therapy developers find manufacturing partners across regions and modalities, with a shared focus on global patient access.

Poolbeg Pharma announces that a South Korean patent relating to POLB 001 has been formally granted.

The Cell and Gene Therapy (CGT) Catapult has published new insights into the advancement of the UK’s cell and gene therapy industry in its Annual Review.

Poolbeg Pharma announces its unaudited interim results for the six months to 30 June 2026.

Poolbeg Pharma reaffirmed that participant recruitment for the POLB 001 TOPICAL trial is progressing well. Following the previously announced six-patient safety cohort, a total of eight participants have now been dosed out of c.30, since the first patient dosed in July 2026.

Positive interim review marks key milestone for POLB 001 clinical development

Regional cluster updates, fresh OLS data, NICE's Enhertu approval and £89.9m for Chemify - catch up on this week's CEO blog.

Global drug development consultancy Boyds has reported robust revenue growth for the financial year ending March 2026, despite the slowdown in the global biotech and pharma markets.

Peptide drug discovery uses peptides to investigate biological targets and develop potential therapeutics. The blog covers their key advantages, applications in screening and SAR, major challenges such as stability and delivery, optimisation strategies, and how o2h Discovery supports peptide synthesis and drug discovery workflows.

Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that it has been selected to present at a number of leading international conferences this September.

MyAmici and My Green Lab announce collaboration to support more sustainable lab purchasing. The integration helps life-science labs consider environmental impact alongside price and availability with other purchasing solutions to aid sustainability.

VectorBuilder and Lir Therapeutics formed a strategic collaboration to develop adeno-associated virus (AAV) capsids.

The Milner Therapeutics Institute (MTI) is proud to be part of a new £20 million Medical Research Council (MRC) investment that will establish a UK Pre-clinical Translational Models Hub.

eXmoor Pharma and Evox Therapeutics announce the successful completion of a technology transfer programme for Evox’s exosome-enabled gene editing technology.

The Milner Therapeutics Institute has joined the o2h Discovery Platinum Partner Programme, enabling eligible companies within its bio-incubator and wider affiliate network to access specialist drug discovery support through the o2h Kickstarter Award.

Poolbeg Pharma today announces that the first patient has been dosed in the POLB 001 TOPICAL clinical trial.

Major VectorBee update reflects VectorBuilder’s continued investment in free, researcher-first tools for genetic engineering and vector design.

Autolomous and Cellular Origins today announce end-to-end integration of their respective platforms, bringing full automation and digitisation to the entire cell therapy manufacturing process.

Global drug development consultancy, Boyds has achieved a Bronze Medal from EcoVadis, a global leader in business sustainability assessments.